Application of Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions between Elexacaftor/Tezacaftor/Ivacaftor and Tacrolimus in Lung Transplant Recipients

• Autori principali: Eunjin Hong (Autore), Eugeniu Carmanov (Autore), Alan Shi (Autore), Peter S. Chung (Autore), Adupa P. Rao (Autore), Kevin Forrester (Autore), Paul M. Beringer (Autore)
• Natura: Libro
• Pubblicazione: MDPI AG, 2023-05-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Elexacaftor/tezacaftor/ivacaftor (ETI) treatment has potential benefits in lung transplant recipients, including improvements in extrapulmonary manifestations, such as gastrointestinal and sinus disease; however, ivacaftor is an inhibitor of cytochrome P450 3A (CYP3A) and may, therefore, pose a risk...